Related Experiment Video
Updated: May 13, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Amylin induces hypoglycemia in mice
Luiz H Guerreiro1, Daniel Da Silva, Mauro Sola-Penna
1Universidade Federal do Rio de Janeiro, Faculdade de Farmácia, Rio de Janeiro, RJ, Brasil.
Anais Da Academia Brasileira De Ciencias
|March 6, 2013
Summary
Amylin, a pancreatic protein, directly lowers blood glucose in normal and diabetic mice without insulin. This study reveals amylin
Area of Science:
- Endocrinology
- Metabolic Research
- Pancreatic Physiology
Background:
- Amylin is a 37-aminoacid pancreatic hormone.
- Amylin influences metabolic processes, including glycemia.
- Previous research indicated amylin increases arterial plasma glucose.
Purpose of the Study:
- To investigate potential additional roles of amylin in glucose metabolism.
- To evaluate amylin's effect on glucose homeostasis independently of insulin.
Main Methods:
- Assessed glucose homeostasis in fasting, conscious mice (normal and diabetic).
- Administered varying doses of mouse amylin subcutaneously.
- Monitored whole blood glucose levels over time post-injection.
Main Results:
- Subcutaneous amylin administration induced a transient decrease in blood glucose in both normal and diabetic mice.
- The hypoglycemic effect was observed in the absence of insulin.
- A dose-dependent response was noted, with effects seen from 0.1 to 50 µg/mouse.
Conclusions:
- Amylin demonstrates a direct glucose-lowering capability.
- Low doses of amylin can effectively control glycemia independently of insulin.
- These findings expand the known functions of amylin in metabolic regulation.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...